Authors

Latest:

Dr Garrido-Laguna on the Mechanism of Action of RMC-6236 in KRAS-Mutant PDAC

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.

Ignacio I. Wistuba, MD

Latest:

Exciting NSCLC Data Updates from ESMO 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

Ignatius Nyatsanza, MD

Latest:

Should You Take a Break After Your Oncology Fellowship?

The question of what to do between completing a fellowship and starting a new job is a big one.

Igor Aurer, MD

Latest:

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

Igor Puzanov, MD

Latest:

Dr. Puzanov on Management of Adverse Events in Melanoma

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Igor Puzanov, MD, MSCI, FACP

Latest:

Tackling the Adverse Effects of Immunotherapy

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

ï¿¼ï¿¼Kar Fai Chow, MD

Latest:

Redefining the Role of Pathology in the Molecular Era: Away From the Microscope? Not So Fast

Andre Goy, MD, discusses how pathologists will continue to play a critical role in oncology care, even with the technological advances of the molecular era.

Ilaria Iacobucci, PhD

Latest:

Genomic Sequencing and Identifying Driver Mutations in AML and MDS

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Ilene H. Zuckerman, PhD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

Imad Tabbara, MD

Latest:

Dr. Tabbara on Treatment for Transplant-Eligible and -Ineligible Patients With Multiple Myeloma

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Inas Abuali, MD

Latest:

Do No Harm

It is hard as a physician not to feel the sting of failure when you lose a patient. Yet, it serves as a reminder that at the end of the day, we uphold our oath by knowing when enough is enough, by ensuring that there is dignity, not only during life, but also in death.

Inas Abuali, MD, FACP

Latest:

Conditions Are Better for Women in Oncology But More Work Needs to Be Done

Despite the strides made by women over the past 170 years, significant disparities remain, especially in academic medicine.

Inga T. Lennes, MD, MBA, MPH

Latest:

Dr. Lennes Discusses Ongoing Research on Screening Techniques for Lung Cancer

Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.

Ingfrid Haldorsen, MD

Latest:

Dr. Haldorsen on Overcoming Challenges With Imaging in Endometrial Cancer

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, on overcoming challenges with imaging in endometrial cancer.

Ingrid A. Mayer, MD

Latest:

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Ingrid A. Mayer, MD, MSCI

Latest:

Development of PI3K Inhibitors in Breast Cancer

The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.

Ingrid A. Mayer, MD, MSCI, Vanderbilt University Medical Center

Insight From: Adam Brufsky, MD, PhD, Pittsburgh

Insight From: Adam Brufsky, MD, PhD, PittsburghÂ

Insight From: Adam Brufsky, MD, Pittsburgh